GCP
DFTX

GSA Capital Partners’s Definium Therapeutics DFTX Stock Holding History

GSA Capital Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$427K Sell
9,073
-9,082
-50% -$224K 0.03% 1105
2026
Q1 		$343K Sell
18,155
-34,100
-65% -$579K 0.02% 1168
2025
Q4 		$700K Sell
52,255
-3,234
-6% -$40K 0.06% 588
2025
Q3 		$654K Buy
+55,489
New +$517K 0.05% 672

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

GSA Capital Partners's DFTX Position: Q2 2026 in Review

GSA Capital Partners reduced its Definium Therapeutics (DFTX) stake by 50% in Q2 2026, selling an estimated $224K and leaving 9,073 shares worth $427K. The position accounts for 0.03% of the portfolio, ranked #1105.

GSA Capital Partners first reported a position in DFTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $700K in Q4 2025. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • GSA Capital Partners held 9,073 shares of Definium Therapeutics worth $427K as of Q2 2026.
  • GSA Capital Partners sold 9,082 Definium Therapeutics shares in Q2 2026, an estimated $224K.
  • Definium Therapeutics made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #1105 holding.
  • GSA Capital Partners first reported a position in Definium Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • GSA Capital Partners's Definium Therapeutics position peaked at $700K in Q4 2025.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.